Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6055 in Relapsed/Refractory B-Cell Malignancies
NCT07493174Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of SYS6055 in B-cell malignancy, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Dose-limiting toxicities at 28 days, Occurrence of Adverse Events and Serious Adverse Events at 24 months and 1 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
SYS6055
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT07493174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493174.